Related Experiment Video
Updated: Sep 30, 2025
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
21.6K
Large granular lymphocytic leukemia: a brief review
Ekta Rahul1, Aparna Ningombam2, Shreyam Acharya2
1Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India.
American Journal of Blood Research
|March 16, 2022
Summary
Large granular lymphocyte (LGL) leukemia is a rare disorder affecting T cells or NK cells. Understanding its molecular pathways and clinical features is crucial for developing targeted therapies and improving patient outcomes.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Large granular lymphocyte (LGL) leukemia is a rare chronic lymphoproliferative disorder.
- It originates from cytotoxic lymphocytes, classified as T-cell or NK-cell derived.
- Subtypes include chronic T-cell leukemia, chronic NK-cell lymphocytosis, and aggressive NK-cell LGL leukemia.
Purpose of the Study:
- To provide a comprehensive overview of LGL leukemia.
- To discuss its epidemiology, pathophysiology, and clinical manifestations.
- To review current and emerging treatment strategies.
Main Methods:
- Review of existing literature on LGL leukemia.
- Analysis of molecular pathways involved in LGL proliferation.
- Discussion of clinical features, diagnostic approaches, and treatment outcomes.
Main Results:
- LGL leukemia is characterized by neutropenia, anemia, and thrombocytopenia, often associated with autoimmune conditions.
- Molecular pathways like JAK-STAT3 and PI3K/AKT are implicated in clonal proliferation.
- Indolent cases typically have a good prognosis, with aggressive NK-cell LGL leukemia being an exception.
Conclusions:
- Advances in understanding molecular pathways are guiding the development of targeted therapies.
- Effective management relies on addressing clinical features and considering immunomodulators and targeted treatments.
- Further research and clinical trials are needed due to the disease's rarity.
